⌕
Harrow · HROW · Nasdaq
Tenet 41 · Weak
Compare
$30.12+6.43%At closeTenet 41 · Weak
$30.12+1.82 (+6.43%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Harrow (HROW) Stock

Harrow (HROW) closed at $30.12 on Nov 13, 2026; its Tenet Score is 41 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

13 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$30.12
Nov 13, 2026
Market cap
$1.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
25.76 – 54.85
low → high
Tenet Score
41/100
Weak · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Harrow Inc scores 41/100. Weak. Strongest on growth, value is the soft spot versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
41/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
20
Quality
42
Health
23
Growth
81

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityDHealthFGrowthBMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
38.7×
price to book value
P/S
3.7×
price to fiscal 2025 sales
ROE
−75%
return on equity
Operating margin
11.2%
fiscal 2025, before interest and tax
Net margin
−9.4%
of revenue kept
Current ratio
2.29
current assets to liabilities
Net debt / EBITDA
12.2×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Harrow Inc

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 61 US ETFs · top wrappers by weightSee all ETFs holding HROW →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Harrow in?

Harrow is in the Healthcare sector and the Drugs industry.

What is Harrow's Tenet Score?

Harrow's Tenet Score is 41 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.